ResMed Inc. (RSMDF)
OTCMKTS
· Delayed Price · Currency is USD
22.00
0.00 (0.00%)
May 8, 2025, 4:00 PM EDT
ResMed Revenue
ResMed had revenue of $1.29B in the quarter ending March 31, 2025, with 7.92% growth. This brings the company's revenue in the last twelve months to $5.02B, up 9.54% year-over-year. In the fiscal year ending June 30, 2024, ResMed had annual revenue of $4.69B with 10.95% growth.
Revenue (ttm)
5.02B
Revenue Growth
+9.54%
P/S Ratio
7.16
Revenue / Employee
503.16K
Employees
9,980
Market Cap
35.93B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Jun 30, 2024 | 4.69B | 462.30M | 10.95% |
| Jun 30, 2023 | 4.22B | 644.87M | 18.02% |
| Jun 30, 2022 | 3.58B | 381.30M | 11.93% |
| Jun 30, 2021 | 3.20B | 239.81M | 8.11% |
| Jun 30, 2020 | 2.96B | 350.44M | 13.44% |
| Jun 30, 2019 | Pro | Pro | Pro |
| Jun 30, 2018 | Pro | Pro | Pro |
| Jun 30, 2017 | Pro | Pro | Pro |
| Jun 30, 2016 | Pro | Pro | Pro |
| Jun 30, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo Inc. | 1.73B |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| Glass House Brands | 200.90M |
| Elite Pharmaceuticals | 70.00M |
| Northwest Biotherapeutics | 1.38M |
| BioStem Technologies | 301.83M |
| American Oncology Network | 1.76B |
ResMed News
- 7 days ago - Top 15 High-Growth Dividend Stocks To Consider For May 2025 - Seeking Alpha
- 8 days ago - Resmed Acquires VirtuOx - GlobeNewsWire
- 12 days ago - Billion-dollar medical start-ups say Trump could force a US move - The Australian Financial Review
- 14 days ago - We reaffirmed our tariff relief in 2008 and 2009, we went back again 3 weeks ago, says Resmed CEO - CNBC
- 15 days ago - ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast - Benzinga
- 15 days ago - ResMed Boasts Double-Digit EPS Growth, Tariff Exemption: Analysts Boost Price Forecast - Benzinga
- 15 days ago - Texas Instruments Posts Better-Than-Expected Results, Joins Community Health Systems, Hasbro, ServiceNow, ResMed And Other Big Stocks Moving Higher On Thursday - Benzinga
- 15 days ago - ResMed declares $0.53 dividend - Seeking Alpha